| Business Summary | | Enchira
Biotechnology
Corporation
is
a
biotechnology
company
incorporating
genetic
recombination,
high-throughput
screening
and
bioprocessing
in
an
integrated,
directed
evolution
technology
platform.
The
Company's
proprietary
platform
technology
may
be
used
to
generate
libraries
of
novel
genes
for
the
creation
of
improved
enzymes
for
a
broad
range
of
applications,
such
as
protein-based
pharmaceuticals,
agricultural
crop
enhancement
and
protection
products,
and
industrial
enzymes
for
the
manufacture
of
specialty
chemicals,
fine
chemicals
and
pharmaceutical
intermediates. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Enchira
Biotechnology
Corporation
develops
and
commercializes
biotechnology-based
processes
for
the
petroleum
refining
and
production
industries.
For
the
six
months
ended
6/30/01,
revenues
rose
48%
to
$531
thousand.
Net
loss
applicable
to
Common
rose
13%
to
$4.2
million.
Revenues
reflect
an
increase
in
sponsored
research
revenues
due
to
the
collaboration
agreement
with
Genecor.
Higher
loss
reflects
an
increase
in
legal
and
personnel
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| William Nasser, 61 Chairman | -- | Peter Policastro, Ph.D, 47 COO,
Chief Exec. Officer, Pres, Director | $221K | Paul Brown, III, 40 VP
of Fin. and Admin. of the Company | 188K | Daniel Monticello, Ph.D, 45 VP-R&D,
Director | 455K | David Carpi, 39 VP-Bus.
Devel. | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|